EO3001 / Edison Oncology - LARVOL DELTA

EO3001: A novel agent for ARID1A mutant cancers (AACR-NCI-EORTC 2025) - "Conclusions and Next Steps These findings suggest that EO3001 holds promise as a targeted therapeutic for ARID1A-mutant cancers, and ongoing work is focused on optimizing its application in clinically relevant settings. A biomarker-driven clinical trial is planed to further evaluate these findings."

Clear Cell Carcinoma • Oncology • Ovarian Cancer • Solid Tumor • ARID1A

Edison Oncology's presentation "EO3001: A novel agent for ARID1A-mutant cancers," highlights the potential of EO3001 as a first-in-class targeted therapeutic for ARID1A-mutant cancers (ACCESS Newswire) - "Edison Oncology Presents...Posters at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics....Preclinical studies demonstrate that EO3001 exhibits potent and selective cytotoxicity in ARID1A-deficient ovarian clear cell and endometrioid cancer models, consistent with enhanced reliance on oxidative phosphorylation (OXPHOS) in these tumors."

Preclinical • Endometrial Cancer • Ovarian Cancer

Investigating the potential of EO3001 as a therapeutic agent for clear cell ovarian cancers harboring ARID1A mutations (AACR 2025) - "EO3001 demonstrated significant differential effects against ARID1A-deficient CCOC cells in both in vitro and ex vivo models. However, hypoxic conditions significantly diminished its efficacy, likely due to a metabolic shift between OXPHOS and glycolysis. Furthermore, Cu(II) concentration in the microenvironment remarkably impacts the efficiency of EO3001."

Oncology • Ovarian Cancer • Ovarian Clear Cell Cancer • Solid Tumor • ARID1A • SLC7A11

Investigating the therapeutic efficacy of EO3001 in clear cell carcinoma of the ovary (AACR 2023) - "We will use the organoids modeling system -using primary endometrial cells harboring ARID1A mutations- to assess the impact of EO3001 on organoid growth and response to stress conditions and evaluate the effect of EO3001 on cancer metastesis by the ex vivo pulmonary metastasis assay (PuMA). Conclusions Exploiting the vulnerability in reliance on OXPHOS in ARID1A-deficient CCC using EO3001 might represent a promising strategy for the treatment of these patients as well as patients harboring other ARID1A-deficient malignancies."

Clinical • Oncology • Ovarian Cancer • Solid Tumor • ARID1A • PIK3CA • SLC7A11

Edison Oncology Announces Presentation of Two Scientific Posters at AACR Annual Meeting (PRNewswire) - "Edison Oncology Holding Corp....is pleased to announce the presentation of two scientific posters at the annual meeting of the American Association of Cancer Research....In a second presentation...Edison Oncology reported that in CRISPR/Cas9 generated isogenic pairs of ovarian cancer cell lines, EO3001 selectively kills ARID1A mutant cancer cells at low nanomolar concentrations compared to 'wildtype' ovarian cancer cells that do not harbor the mutation....The poster describes that by directly inhibiting the action of certain mitochondrial proteins required for the function of the OXPHOS pathway, EO3001 may result in energy deprivation and apoptosis the of metabolically overactive ARID1A mutant tumor cells."

Preclinical • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor • ARID1A